Peter Ansell

机构：AbbVie (United States) · ORCID：0000-0002-4088-2840

发表论文 201 篇 · 总被引 4605 次 · h-index 31

代表论文

• Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein–Overexpressing Advanced Nonsquamous EGFR -Wildtype Non–Small Cell Lung Cancer in the Phase II LUMINOSITY Trial (2024 · Journal of Clinical Oncology · 被引 162)
• MET (c-Met) protein overexpression is an emerging protein biomarker in non-small cell lung cancer (2025 · npj Precision Oncology · 被引 8)
• A phase 1b study of cofetuzumab pelidotin monotherapy in patients with PTK7-expressing recurrent non-small cell lung cancer (2025 · Lung Cancer · 被引 6)
• 1397P Prevalence, molecular characterization, and prognosis of MET–overexpressing non-small cell lung cancer (NSCLC) in a real-world patient cohort (2023 · Annals of Oncology · 被引 4)
• Folate receptor alpha (FRα; FOLR1) expression and persistence in ovarian cancer in clinical trial samples and real-world patient cohort. (2025 · Journal of Clinical Oncology · 被引 3)
• Prevalence, molecular characterization, and prognosis of c-Met protein overexpression in a real-world cohort of patients with non-squamous non-small cell lung cancer (2025 · Acta Oncologica · 被引 2)